
Hey there, it’s Vadim 👋
Happy summer days!
First, a quick thank you to everyone who filled out the survey last week about what you'd like to see more of in Bio Founder GPS.
It was super helpful to see that fundraising is still top of mind for most of you, with many of you enjoying the deep dives, while some interested in seeing some bite-sized content.
So today I'm going to try to cover both camps.
We'll talk about fundraising, and we'll do it in a format that pairs a little better with your Sunday brunch, whether you're surviving another unpredictable heat wave here in NYC or reading this by a lake or a European beachside enclave.
If you're in that second camp, please do have a tropical beverage on my behalf 🙂
Now, let’s have a heart to heart about your investor list.
This week, I actually wanted to write a simple issue about which life science funds have raised fresh capital over the past 18 months.
The logic seemed straightforward: find the funds that recently closed, figure out what they invest in, and provide you with a list that hopefully could be of use for your upcoming fundraise.
Then I started looking more closely at what my research generated. And I realized that in a long list of funds that seemed like safe bets and good “anchor tenants”, the truth was a lot more nuanced.
And as I started reviewing each fund in earnest, the list grew a lot shorter.
That exercise has turned into something considerably bigger than one issue, and I'll share the full version later this year.
But in the meantime, it left me with a question that I couldn’t quite unsee:
How many investors on your list could realistically invest in your company, in this round, today?
Because that’s a very different question from who invests in “biotech”, and as I’m finding, the gap between the two is wider (and more in flux) than most founders expect - myself included.
So with that in mind, let’s talk about the 5 ways your investor list may be lying to you 👇
LIE #1
“They invest in ‘biotech’, so they’re a fit”
What a fund says vs. what a fund does
Almost every founder I work with checks whether an investor is a “fit”.
Usually that means visiting the fund's website, reading a few paragraphs about its thesis, and checking whether words like therapeutics, techbio, seed, or “life sciences” appear somewhere on the page.
That's a reasonable place to start, and I'd rather founders do it than not. But a website tells you what a firm wants the market to know about its strategy.
The checks it has written over the last year tell you how that strategy actually gets deployed.
A fund may describe itself as “first money in” while its last several investments all came after the company had already raised a seed round and generated in-vivo data. This is fair, and happens often: the language reflects how the firm sees itself, and the deals reflect what it has actually been comfortable underwriting recently.
Another may describe its thesis as backing disruptive technologies across life sciences, while nearly every new check for the past 18 months has gone to something with a computational or AI layer on top. If you're a wet lab therapeutics company, that fund is in your sector by semantics, but realistically, it may not be the best use of your time.
When the website and the deal data disagree, I'd put my money on the deals.
My advice: pull up the fund's new investments from the last 12-18 months and answer a few questions about them:
What did they actually invest in? Was it therapeutics, diagnostics, tools, techbio, SaaS, etc? See if, and where, the fund is clustering its bets.
What did each company actually have on the day the check landed? Not what they have today (which is a common misconception).
How old were those companies at first check? Incorporated eight months ago, or four years ago? Company age at first investment can be telling, and it’s usually public data.
Did the fund lead, or follow? A firm that has never led a round can be a great second call, but it will be challenging for it to truly unlock your raise.
Where did its portfolio companies come from? If four of the last five spun out of the same two universities or came through the same accelerator, that’s worth taking into account.
Most of this is easier to find than founders expect.
The fund's portfolio page gives you the roster, and each portfolio company's own funding announcement will usually name who led the round. Board seat announcements are often a stronger signal than press releases, since a partner taking a board seat is a much bigger commitment than being listed as a participant.
Collectively, all of this will be much more telling than what the fund includes in their marketing materials.
LIE #2
“They have capital, so they can invest in me”
Some funds are closed to you before you start.
This was the thing that jumped out at me most during the research.
I reviewed 41 life science fund closes since January 2025. Of those, I'd only put seven on a pre-seed or seed founder's list as realistic first-check prospects. A handful more are close calls depending on your geography or disease area.
Now, that doesn't mean the other 34 weren't investing in life sciences. They absolutely were, and some of them were writing very sizable checks.
Their capital simply had a different job.
Take Atlas Venture Opportunity Fund III, which closed $400M last September. On the surface it checks several boxes a biotech founder would search for: recent close, major life science investor, and plenty of dry powder.
But it's an opportunity fund: by definition, the capital is reserved for companies Atlas already backs.
No amount of pitch refinement or networking changes that.
The same issue shows up with royalty and credit funds, later-stage vehicles, company-creation models, and funds restricted to a particular institution or geography.
My advice: don't stop at “does this firm invest in companies like mine?” Ask what the specific vehicle you're targeting was created to fund.
A few things worth checking:
Does the firm run more than one fund? Plenty of firms keep an early-stage vehicle and a growth or opportunity vehicle side by side. Atlas is a good example - its $450M Fund XIV closed in December 2024 and does invest at seed. The fund that made headlines last September simply isn't the one that would write your check.
Does the name give it away? Words like opportunity, growth, select, continuation, credit, royalty, or lending usually mean the vehicle exists for something other than a first check into a new company.
Are there strings attached to the capital? Some funds can only back companies built on a particular university's IP, or headquartered in a specific state, or working in one disease area, because that's what the LPs signed up for. That isn't a preference you can pitch your way around.
While researching this may give you an answer that you may not want to hear, you’re much better off finding this out after a 5 min search than weeks of emails and LinkedIn DMs that go nowhere.
LIE #3
“They just closed a fund, so they’re active”
A fund that closed is not proof it will invest.
Fund vintage is genuinely one of the most valuable pieces of information you can have about an investor, and I don't want to talk anyone out of using it.
A newly closed fund usually has a longer investment horizon ahead of it than one five or six years into its life, so knowing who recently closed should absolutely shape how you prioritize.
But it isn't quite the given that founders treat it as, and it still needs pressure testing.
A firm may spend months staffing up, building its pipeline, or working through deals that were already underway before the close. And occasionally the picture changes remarkably quickly.
Nexus NeuroTech Fund II closed $126M in March 2025 and went on to back seven companies. Twelve months later, the firm had concluded operations after being absorbed into Bayshore Global Management, the single-family office of Google co-founder, Sergey Brin.
My advice: treat the close as the start of the question rather than the answer, and look for evidence of what's happened since:
Have they announced a new investment since the close? Not a follow-on into a company they already owned. A new name, dated after the close, is the strongest proof a fund is open for business.
Has a partner taken a new board seat? Similar to what we covered in Lie#1, this is a real signal and commitment from the fund.
Is the pace consistent with the fund size? A $150M fund that has made two investments in 18 months is telling you something about how quickly it intends to move.
Whether capital is fresh is very useful information, but nothing beats knowing what a fund is actually doing with the capital it has on hand.
LIE #4
“They don’t back my competitor, so we’re clear”
Portfolio overlap cuts both ways
Most founders know to scan an investor's portfolio for obvious conflicts.
The problem is that the overlap that matters is usually less obvious than a direct competitor.
Maybe the fund backs a company pursuing the same mechanism in a different indication. Maybe it has invested in a platform whose scope quietly extends into your space. Maybe there's no competitor at all, but the firm has already made the strategic bet your company would represent.
That can work against you, but it can also work in your favor.
A partner who already believes in your area may understand the science faster, know the competitive landscape better, and arrive with conviction that another investor would need six months of diligence to build. Some funds are happy to build clusters around themes they know well. Others guard portfolio territory carefully.
So I wouldn't automatically take out a fund the moment you spot bets in spaces adjacent to yours.
My advice: look past direct competitors, then work out how the firm actually behaves:
How close is the overlap, really? Same mechanism in a different indication is a real conflict. A platform company two steps removed from your space usually isn't, though it may still shape how the partner thinks about your market.
Do they bet once per space, or multiple times? Scan the portfolio for areas where they've backed two or three companies rather than just one. A firm that doubles down is a very different prospect than one that spreads its bets.
Can you ask someone? Speaking to founders of their portfolio companies, EIR’s, or even asking members of the fund directly about how they think about the space can give you insights you may not otherwise get by just looking at data.
That answer can be very informative and help add your own conviction about where a fund really stands and how much of a fit it really is.
LIE #5
“They were a fit when I added them”
Every investor list has a half-life
This may not sound like a lot, but it can really be a silent killer.
Your investor list has a half-life. Nothing dramatic happens to it on any given day, which is exactly why it's easy to miss. A spreadsheet that you put together last year before JPM still looks.. “pretty good”.
And of course, Excel has never been the one to page you with urgent updates 🙂
In reality, however, the funds respond to the market, and the market is always changing.
Partners move, and strategies evolve. Funds get further into their deployment cycles. A new portfolio company creates a conflict. A firm that was aggressively backing new companies starts reserving more capital for the ones it already owns.
Your own relationship with the investor changes too.
Maybe you already received a pass, maybe someone told you to come back after a milestone. Maybe you met a partner at a conference and the follow-up note is still sitting in your drafts, while the fund remains labeled “target” in your spreadsheet.
My advice: treat your investor universe as a living dataset rather than a research project you finished:
Put a “last checked” date on every row. If you can't say when you last looked at a fund, you may be building your strategy on points of reference that are no longer there.
Log the interaction history, not just the name. Passes, referrals, “come back after X,” the partner you met at a conference. That context is what helps you to truly nurture relationships, but until it’s in the tracker, you’re relying on your own recall - and luck.
Re-check the top of the list before each push. You don't need to refresh 150 names. Refreshing the 20 you're about to email is enough, and if you do it often, it won’t be as big of a time commitment as it first may appear.
YOUR ACTION POINTS
So, what should happen to the list?
My advice: sort the list into three buckets
I don't think the answer is simply to trim your investor list.
A fund that isn't right for this round may be exactly the investor you want to know before the next one, and deleting every imperfect fit throws away institutional knowledge that you worked hard to build.
Instead, I'd put each name into one of three buckets:
Approach now: there's a credible reason this fund could invest in this company, in this round, right now.
Warm up for later: real fit, but the timing, stage, milestone, or relationship isn't there yet.
Stop counting it as pipeline: no credible path to a check under current circumstances.
That third category matters more than it sounds, and here's why.
The biggest cost of a poorly qualified investor list isn't even the extra research or the emails that go unanswered. It's the conclusion you draw from their presence.
Here is what I mean - imagine you send your deck to 50 investors and only a handful respond.
It's very easy to look at that and decide that maybe your story isn't landing. Maybe the science isn't compelling enough or maybe investors don't believe the market is there. Maybe the deck needs another rewrite, yet again.
But what if half of those investors were never realistic prospects to begin with?
Maybe it was the wrong vehicle, or the wrong stage in practice. Or existing portfolio overlap.. or no longer deploying into new companies.
Now that response rate is telling you something completely different.
The key thing to watch out for is that a bad investor list can hand you a false read on your own company, usually right at the moment when you can least afford it.
THAT’S A WRAP
Your homework for this week
Open your investor list and look at the top 25 names - could you defend why each one belongs there?
Not why they're “biotech” investors, or that they came bundled on a list you got from a LinkedIn post 5 months ago.
Why are they genuinely worth your time in this round?
Whatever survives that is your actual pipeline. My guess is it's smaller than the spreadsheet suggests, but also, that it may be considerably more useful.
And if you try it - respond to this email and let me know how it goes!
Until next week!
- Vadim
PS: I've been working on something behind the scenes to help life science founders build better-qualified investor lists and run the fundraising process, and I’m considering opening up free beta access to a select few founders later this month.
If that sounds like it may be helpful, fill out the short survey below about your fundraising experience, and leave your email. Takes 2-3 min and you’ll be the first in line. Also, I’ll be super grateful for your perspective 🙂
When you’re ready, here’s how I can help:
Pitch Deck Audit - a second pair of eyes on your deck before you get in front of investors. I'll go through it the way an investor would and tell you what's landing, what isn't, and what questions you'll get asked. You get slide-by-slide feedback, a custom list of investors, and we spend an hour going through everything live.
Book a strategy call - sometimes it just helps to think out loud with someone who's been on the other side of the table. If that sounds useful, fill out the form below and let’s chat!